Japanese regulatory authorities on November 20 announced label updates for two leukemia treatments from Chugai Pharmaceutical and Janssen Pharmaceutical (J&J), issued in tandem with the day’s approval of AbbVie’s Venclexta (venetoclax) for combination use with both medicines. Subject to the…
To read the full story
Related Article
- Japan Approves Label Expansions for Braftovi, Augtyro, Uplizna, and More
November 21, 2025
REGULATORY
- DPP Lawmaker Calls for Inflation Relief in 2027 Off-Year Drug Price Revision
August 19, 2026
- CEA Review Group Wraps Up Technical Debate, Urges More Company Access
August 19, 2026
- Japan Panel to Weigh Keytruda SC, J&J Psoriasis Pill among 6 NMEs on Aug. 24
August 18, 2026
- PMDA Urges Quality-Driven Biosimilar Development as CES Waivers Take Hold
August 18, 2026
- Japan Calls for APOE Testing before Leqembi, Kisunla Treatment
August 18, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





